Micuda, Stanislav
Poslední změna: 05.01. 2015

Vybrané publikace od roku 2005

Lenčová-Popelová O., Jirkovský E., Mazurová Y., Lenčo J., Adamcová M., Šimůnek T., Geršl V., Štěrba M. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014; 9(5): e96055.


Vávrová A., Jansová H., Macková E., Macháček M., Hašková P., Tichotová L., Štěrba M., Šimůnek T. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One. 2013;8(10):e76676.


Štěrba M., Popelová O., Vávrová A., Jirkovský E., Kovaříková P., Geršl V., Šimůnek T. Oxidative stress, redox signaling and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxidants & Redox Signaling 2013; 18(8): 899-929.


Jirkovský E., Lenčová-Popelová O., Hroch M., Adamcová M., Mazurová Y., Vávrová J., Mičuda S., Šimůnek T., Geršl V., Štěrba M. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology 2013; 311(3): 191-204.


Jirkovský E., Popelová O., Křiváková-Staňková P., Vávrová A., Hroch M., Hašková P., Brčáková-Doleželová E., Mičuda S., Adamcová M., Šimůnek T., Červinková Z., Geršl V., Štěrba M. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on Nrf2 and mitochondrial biogenesis pathways. Journal of Pharmacology and Experimental Therapeutics 2012; 343(2): 468-78.


Neckář J., Boudíková A., Mandíková P., Štěrba M., Popelová O., Mikšík I., Dabrowská L., Mráz J., Geršl V., Kolář F. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Canadian Journal of Physiology and Pharmacology 2012; 90(9): 1303-10.


Nachtigal P., Štěrba M., Popelová O., Večeřová L., Kudláčková Z., Jirkovský E., Geršl V. Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histology and Histopathology 2011; 26(5): 551-562.


Štěrba M., Popelová O., Lenčo J., Fučíková A., Brčáková E., Mazurová Y., Jirkovský E., Šimůnek T., Adamcová M., Mičuda S., Stulík J., Geršl V. Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology 2011; 50(5): 849-862.


Vávrová A., Popelová O., Štěrba M., Jirkovský E., Hašková P., Mertlíková-Kaiserová H., Geršl V., Šimůnek T. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology 2011; 85(5): 525-535.


Popelová O., Štěrba M., Hašková P., Šimůnek T., Hroch M., Gunčová I., Nachtigal P., Adamcová M., Geršl V., Mazurová Y. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. British Journal of Cancer 2009; 101(5): 792-802.


Šimůnek T., Štěrba M., Popelová O., Adamcová M., Hrdina R., Geršl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports 2009; 61(1): 154-171.


Šimůnek T., Štěrba M., Popelová O., Kaiserová H., Adamcová M., Hroch M., Hašková P., Poňka P., Geršl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology 2008; 155(1): 138-48.


Popelová O., Štěrba M., Šimůnek T., Mazurová Y., Gunčová I., Hroch M., Adamcová M., Geršl V. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. Journal of Pharmacology and Experimental Therapeutics 2008; 326(1): 259-269.


Šimůnek T., Štěrba M., Popelová O., Kaiserová H., Potáčová A., Adamcová M., Poňka P., Geršl V. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity. Hemoglobin 2008; 32(1-2): 207-15.


Kaiserová H., Šimůnek T., Štěrba M., den Hartog G. J. M., Schröterová L., Popelová O., Geršl V., Kvasničková E., Bast A. New iron chelators in anthracycline-induced cardiotoxicity. Cardiovascular Toxicology 2007; 7(2): 145-50.


Adamcová M., Šimůnek T., Kaiserová H., Popelová O., Štěrba M., Potáčová A., Vávrová J., Maláková J., Geršl V. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 2007; 237(1-3): 218-28.


Potáčová A., Adamcová M., Čajnáková H., Hrbatová L., Štěrba M., Popelová O., Šimůnek T., Poňka P., Geršl V. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopyathy: A useful tool for assessment of cardioprotective agents. Physiological Research 2007; 56(2): 251-4.


Štěrba M., Popelová O., Šimůnek T., Mazurová Y., Potáčová A., Adamcová M., Gunčová I., Kaiserová H., Palička V., Poňka P., Geršl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology 2007; 235(3): 150-166.


Štěrba M., Popelová O., Šimůnek T., Mazurová Y., Potáčová A., Adamcová M., Kaiserová H., Poňka P., Geršl V. Cardioprotective effects of a novel iron chelator – pyridoxal 2-chlorobenzoyl hydrazone – in the rabbit model of daunorubicin-induced cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 2006; 319(3): 1336-1347.


Adamcová M., Štěrba M., Šimůnek T., Potáčová A., Popelová O., Geršl V. Myocardial regulatory proteins and heart failure. European Journal of Heart Failure 2006; 8(4): 333-42.


Šimůnek T., Boer C., Bouwman R. A., Vlasblom R., Versteilen A. M., Štěrba M., Geršl V., Hrdina R, Poňka P., de Lange J. J., Paulus W. J., Musters R. J. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. Journal of Molecular and Cellular Cardiology 2005; 39(2): 345-54.


Šimůnek T., Štěrba M., Holečková M., Kaplanová J., Klimtová I., Adamcová M., Geršl V., Hrdina R. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals 2005; 18(2): 163-9.


Adamcová M., Štěrba M., Šimůnek T., Potáčová A., Popelová O., Mazurová Y., Geršl V. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opinion On Drug Safety 2005; 4(3): 457-72.


Šimůnek T., Klimtová I, Kaplanová J, Štěrba M., Mazurová Y, Adamcová M, Hrdina R, Geršl V, Poňka P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacological Research 2005; 51(3): 223-31.

Kalendář akcí

<říjen 2019>
poútstčtsone
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
Dnes: